摘要:
A 1,2,4-Triazole derivative of formula 1 or a non-toxic salt thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative or the salt as an active ingredient are provided.
摘要:
A pyrazole-3-one derivative of formula 1 or a non-toxic salt thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative or the salt as an active ingredient are provided: wherein: R1 and R2 each independently represent C1-C3 alkyl, aryl, or substituted aryl; R3 represents amino or methyl; R4 and R5 each independently represent hydrogen, C1-C3 alkyl, halogen, methyl substituted with halogen, C1-C3 alkoxy, cyano, or nitro; or a non-toxic salt thereof.
摘要:
A 2-thioxothiazole derivative of formula 1 or a non-toxic salt thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative or the salt as an active ingredient are provided: wherein: R represents hydrogen or methyl; X represents hydrogen, methyl, halogen, nitro, or methanesulfonyl.
摘要:
A thiazolidine-4-one derivative of formula 1 or a non-toxic salt thereof, a preparation method thereof, and a pharmaceutical composition containing the derivative or the salt as an active ingredient are provided: wherein: R1 and R2 each independently represent hydrogen, C1-C3 alkyl, halogen, methyl substituted with halogen, C1-C3 alkoxy substituted with halogen, cyano, or nitro.
摘要:
The present invention relates to a novel 4′-methanesulfonyl-biphenyl derivative having a structure of formula 1 and its pharmaceutically acceptable salts as a highly selective cyclooxygenase-2 inhibitor. Wherein, R1 and R2 are defined in this specification respectively.
摘要:
The present invention relates to a novel 3,4-dihydro-1H-naphthalene derivative having a structure of formula 1 or formula 2, its pharmaceutically acceptable salts and their geometric isomers as a highly selective cyclooxygenase-2 inhibitor. Wherein, R1, R2, X, A and Q are defined in this specification respectively.
摘要:
The present invention relates to a novel 1H-indole derivative having a structure of formula 1 and its pharmaceutically acceptable salts as a highly selective cyclooxygenase-2 inhibitor. Wherein, X, Y, and Q are defined in this specification respectively.
摘要:
The present invention relates to a novel 3,4-dihydro-1H-naphthalene derivative having a structure of formula 1 or formula 2, its pharmaceutically acceptable salts and their geometric isomers as a highly selective cyclooxygenase-2 inhibitor. Wherein R1, R2, X, A and Q are defined in this specification respectively.
摘要翻译:本发明涉及具有式1或式2结构的新型3,4-二氢-1H-萘衍生物,其药学上可接受的盐及其几何异构体作为高度选择性的环氧合酶-2抑制剂。在R 1, R 2,X,A和Q分别在本说明书中定义。
摘要:
The present invention relates to compounds of chemical formula 1 and having CCR2 (chemokine receptor 2) antagonistic effects, and salts or isomers thereof. These compounds are very useful for treating, preventing, or relieving rheumatoid arthritis, arteriosclerosis, multiple sclerosis, asthma, and various diseases related to CCR2. wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 is the same as defined in the specification.
摘要:
The present invention relates to a composition for treatment and prevention of cardiovascular diseases, containing an extract of Lindera obtusiloba. More particularly, the extract of Lindera obtusiloba strongly inhibits NAD(P)H oxidases, which are the main cause of vascular diseases, and at the same time, regulates contraction and relaxation of vascular smooth muscles to manifest a potent vasorelaxant effect, thereby improving the blood pressure regulation and vascular endothelial dysfunction. Therefore, a composition containing this as an active ingredient can be usefully utilized as a pharmaceutical product or health functional food product for the prevention and treatment of cardiovascular diseases.